Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Contingent Incentives Plus Bupropion for Smoking in People With Schizophrenia

This study has been completed.
Sponsor:
Collaborator:
National Institute on Drug Abuse (NIDA)
Information provided by (Responsible Party):
Jennifer Tidey, Brown University
ClinicalTrials.gov Identifier:
NCT00136760
First received: August 25, 2005
Last updated: October 5, 2015
Last verified: April 2013
Results First Received: November 16, 2012  
Study Type: Interventional
Study Design: Allocation: Randomized;   Endpoint Classification: Efficacy Study;   Intervention Model: Factorial Assignment;   Masking: Double Blind (Subject, Outcomes Assessor);   Primary Purpose: Treatment
Conditions: Schizophrenia and Disorders With Psychotic Features
Tobacco Use Disorder
Interventions: Drug: Bupropion
Drug: Contingent reinforcement plus placebo
Drug: non-contingent reinforcement plus bupropion
Drug: Non-contingent reinforcement plus placebo

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
Participants were recruited from the community, using advertisements, and were recruited from an outpatient clinic at a local VA medical Center.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
Participants underwent telephone and in-person screening for eligibility criteria.

Reporting Groups
  Description
CM + BUP Contingent reinforcement plus bupropion
CM + PLA Contingent reinforcement plus placebo
NR + BUP Non-contingent reinforcement plus bupropion
NR + PLA Non-contingent reinforcement plus placebo

Participant Flow:   Overall Study
    CM + BUP   CM + PLA   NR + BUP   NR + PLA
STARTED   12   16   11   13 
COMPLETED   12   16   11   13 
NOT COMPLETED   0   0   0   0 



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
CM + BUP Contingent reinforcement plus bupropion
CM + PLA Contingent reinforcement plus placebo
NR + BUP Non-contingent reinforcement plus bupropion
NR + PLA Non-contingent reinforcement plus placebo
Total Total of all reporting groups

Baseline Measures
   CM + BUP   CM + PLA   NR + BUP   NR + PLA   Total 
Overall Participants Analyzed 
[Units: Participants]
 12   16   11   13   52 
Age 
[Units: Participants]
         
<=18 years   0   0   0   0   0 
Between 18 and 65 years   12   12   10   13   47 
>=65 years   0   4   1   0   5 
Age 
[Units: Years]
Mean (Standard Deviation)
 42.9  (11.9)   46.3  (6.7)   43.7  (7.3)   46.9  (6.8)   45.1  (8.2) 
Gender 
[Units: Participants]
         
Female   4   6   3   2   15 
Male   8   10   8   11   37 
Region of Enrollment 
[Units: Participants]
         
United States   12   16   11   13   52 


  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Urinary Cotinine   [ Time Frame: 3 weeks ]

2.  Secondary:   Cigarettes Smoked Per Day   [ Time Frame: 3 weeks ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information
  Hide More Information

Certain Agreements:  
All Principal Investigators ARE employed by the organization sponsoring the study.


Results Point of Contact:  
Name/Title: Jennifer Tidey, Ph.D.
Organization: Brown University
phone: 401-863-6418
e-mail: Jennifer_Tidey@brown.edu


Publications of Results:

Responsible Party: Jennifer Tidey, Brown University
ClinicalTrials.gov Identifier: NCT00136760     History of Changes
Other Study ID Numbers: NIDA-17566-1
R01DA017566 ( US NIH Grant/Contract Award Number )
R01-17566-1
Study First Received: August 25, 2005
Results First Received: November 16, 2012
Last Updated: October 5, 2015
Health Authority: United States: Federal Government